Psychemedics

Psychemedics Forward P/E

The Forward P/E Ratio of Psychemedics (PMDI) as of Oct 16, 2026 is -4.60. In the previous year, Forward P/E Ratio was -2.06 — a change of 123.21% (lower).

Forward P/E

-4.60

YoY

123.21%

Last updated:

Forward P/E Ratio of Psychemedics is 2024 -4.60 . Forward P/E Ratio of Psychemedics was 2023 -2.06 . It decreases by 123.21% lower compared to the previous year.

The Psychemedics Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2017
1.40 USD
Jan 1, 2018
1.87 USD
Jan 1, 2019
5.56 USD
Jan 1, 2020
-2.22 USD
Jan 1, 2021
-12.88 USD
Jan 1, 2022
-7.90 USD
Jan 1, 2023
-2.06 USD
Jan 1, 2024
-4.60 USD
The Psychemedics Forward P/E history
YEARForward P/EYoY
-4.60+123.21%
-2.06-73.90%
-7.90-38.65%
-12.88+480.30%
-2.22-139.91%
5.56+197.40%
1.87+33.62%
1.40+9.15%
1.28-77.40%
5.67+112.58%
2.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Psychemedics Stock analysis

What does Psychemedics do? Psychemedics Corp, trading under the ticker PMDI, is a U.S.-based company headquartered in Acton, Massachusetts. The company specializes in drug testing services, focusing on the analysis of hair samples to detect the presence of drugs of abuse. With 204 full-time employees, Psychemedics operates within the Health Care sector, specifically in the Health Care industry. The company's primary service involves conducting drug tests and reporting results to clients, including training for sample collection and storage of positive samples for a fee per unit tested. Its testing methodology provides detailed information on the approximate amount of drug ingested and historical data on drug use patterns over time. Psychemedics went public on January 22, 1987, marking the beginning of its journey as a publicly traded entity. The company's website, https://www.psychemedics.com/, serves as a primary source of information for its services and operations. While the company's core business is centered on drug testing, it does not disclose specific product names or additional services beyond the scope of hair sample analysis and reporting. Psychemedics maintains a presence in the U.S. market, with its operations primarily focused on providing reliable and detailed drug testing solutions to its clients. The company's approach to testing emphasizes both the immediate detection of drug use and the ability to track usage patterns over extended periods, offering a comprehensive service for its customers. Psychemedics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Psychemedics stock

Forward P/E Ratio of Psychemedics is -4.60 in 2024.

Forward P/E Ratio of Psychemedics changed from -2.06 to -4.60, representing a 123.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Psychemedics since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Psychemedics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Psychemedics

All Key Metrics — Psychemedics